IMI launches EUR 130 million Calls for proposals with focus on Alzheimer’s disease, big data, vaccines, and more

Brussels, Belgium, 19 July 2017 – Today, the Innovative Medicines Initiative (IMI) is launching two new Calls for proposals with topics on Alzheimer’s disease, big data, vaccines, autoimmune disease, the blood-brain barrier, drug development, and the exploitation of IMI project results. The total budget for the two Calls stands at just over EUR 130 million. Around half of this comes from the European Commission’s Horizon 2020 programme. The other half comes from EFPIA companies as well as IMI Associated Partners.

Pierre Meulien, IMI Executive Director commented: ‘As these new Call topics show, there are still many challenges and unanswered questions in medical research and drug development. I am optimistic that by bringing together the best people from the public and private sectors, the Innovative Medicines Initiative will help to make progress in these important areas and contribute to accelerating medicines development.’

 Notes to Editors

 IMI2 – Call 11

One topic on ‘Exploitation of IMI project results’

Deadline for submission of proposals: 24 October 2017

More information:

Sign up for the webinar on IMI2 – Call 11 (Wednesday 26 July at 14.30)

IMI2 – Call 12

  • Topic 1: Development and validation of technology enabled, quantitative and sensitive measures of functional decline in people with early stage Alzheimer’s disease (RADAR-AD)
  • Topic 2: FAIRification of IMI and EFPIA data
  • Topic 3: Development of sensitive and validated clinical endpoints in primary Sjögren’s Syndrome (pSS)
  • Topic 4: European Health Data Network (EHDN)
  • Topic 5: Analysing the infectious disease burden and the use of vaccines to improve healthy years in aging populations
  • Topic 6: Discovery and characterisation of blood-brain barrier targets and transport mechanisms for brain delivery of therapeutics to treat neurodegenerative & metabolic diseases
  • Topic 7: European Screening Centre: unique library for attractive biology (ESCulab)

Deadline for submission of proposals: 24 October 2017

 More information:

Press contact

Catherine Brett – External Relations Manager

Tel: +32 2 541 8214 | Mobile: +32 484 896227 | E-mail: Cette adresse e-mail est protégée contre les robots spammeurs. Vous devez activer le JavaScript pour la visualiser.

About the Innovative Medicines Initiative

The Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, the next generation of medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players involved in healthcare research, including universities, pharmaceutical companies, other companies active in healthcare research, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. This approach has proven highly successful, and IMI projects are delivering exciting results that are helping to advance the development of urgently-needed new treatments in diverse areas.

IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). Through the IMI 2 programme, IMI has a budget of €3.3 billion for the period 2014-2024. Half of this comes from the EU’s research and innovation programme, Horizon 2020. The other half comes from large companies, mostly from the pharmaceutical sector; these do not receive any EU funding, but contribute to the projects ‘in kind’, for example by donating their researchers’ time or providing access to research facilities or resources.

More info on IMI:  

Follow us on Twitter: @IMI_JU

Watch the latest video on IMI